Recruiting
Phase 2
Phase 3

Testing the Addition of Trastuzumab or Trastuzumab/Pertuzumab to the Usual Chemotherapy for HER2 Positive Endometrial Cancer

Sponsor:

National Cancer Institute (NCI)

Code:

NCT05256225

Conditions

Endometrial Carcinoma

Endometrial Clear Cell Adenocarcinoma

Endometrial Dedifferentiated Carcinoma

Endometrial Endometrioid Adenocarcinoma

Endometrial Mixed Cell Adenocarcinoma

Eligibility Criteria

Sex: Female

Age: 18+

Healthy Volunteers: Not accepted

Interventions

Biospecimen Collection

Carboplatin

Computed Tomography

Echocardiography

High-Dose-Rate Vaginal Cuff Brachytherapy

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information